fbpx
<span style="color: #047491;">NOT</SPAN> ALL DNA TESTS <br>ARE THE <span style="color: #047491;">SAME</SPAN>, OURS IS <br><span style="color: #F06B30;">CLINICALLY</span> ACCREDITED

NOT ALL DNA TESTS
ARE THE SAME, OURS IS
CLINICALLY ACCREDITED

Singapore Accreditation Council_Logo
First Clinical Recommended Genome-Wide Pharmacogenomics_Award
Largest Clinical Accredited Genome-Wide Pharmacogenomics_award
Health Sciences Authority_Logo
United Kingdom Accredited Services_Logo
NQA_Logo
Singapore Accreditation Council_Logo
First Clinical Recommended Genome-Wide Pharmacogenomics_Award
Largest Clinical Accredited Genome-Wide Pharmacogenomics_award

Personalized & Tailored

Optimizing Treatment Can Take Us From Harm To Healing

Every year, countless people are hurt or lose hope when medications cause side effects or fail to work.

6ᵗʰ

Adverse Drug Reactions (ADRs) are the 6ᵗʰ leading cause of death worldwide ¹ ².

> 50%

of patients are non-adherent to treatment, due to adverse effects or lack of effectiveness ³.

52%

of outpatient drug-related complications could have been avoided ⁴.

Trust The Science

Pharmacogenomics offers the potential to ensure that individuals only take medications that are effective for them. Did you know;

80%

Pharmacogenomics is responsible for ~ 80% variability in genes associated with drug safety and efficacy ⁵.

~ 30%

reduction in Adverse Drug Reactions (ADRs) cases with pharmacogenomic-guided prescription ⁶.

~ 70%

of Physicians modified drug or dosage using Pharmacogenomics testing to reduce Adverse Drug Reactions (ADRs) ⁶.

BASED ON TRUE STORY FROM THE LANCET

A TRAGIC LOSS THAT COULD HAVE BEEN PREVENTED

A 13-day-old infant tragically passed away from morphine poisoning after the mother, unknowingly a CYP2D6 ultra-rapid metabolizer, took a common codeine-based painkiller. Her body converted codeine into dangerously high morphine levels, which were then passed to her baby through breast milk.

This heartbreaking case — reported in The Lancet — highlights the urgent need for pharmacogenomic testing. If the mother had known her genetic profile, she could have avoided codeine and chosen a safer pain relief option.

Our Services

Unlock Your Health With Precision Diagnostics

At Precision Diagnostic, we offer advanced genetic profiling to provide personalized health strategies based on your unique DNA.

PRECISE Pharmacogenomics:
Smarter Medications, Better Outcomes

• Personalized medication plans
• Reduced side effects
• Faster, more effective treatments
• Smarter spending with fewer ineffective treatments

PRECISE Nutrigenomics:
Nutrition Tailored to You

• Customized diet and supplement plans
• Disease prevention
• Weight management
• Enhanced sport performance

PRECISE ONCO+:
Personalised Cancer Treatment Starts Here

• Targeted drug selection
• Reduced toxicity
• Improved treatment outcome
• Data-driven guidance for treatment planning

backed by science

Built On The Most Up-To-Date Clinical Evidence

Our reports are grounded in the latest scientific research and globally accepted clinical guidelines. Every recommendation is aligned with trusted sources, ensuring you receive clinically actionable insights that evolve with modern medicine.

our collaborators and partners

Trusted By

We are honoured to work alongside esteemed organisations across education, healthcare, and wellness. These valued collaborators support our efforts in research, professional training, and community outreach.

Advocated by

Our Board Of Advisors

Board Member PRECISE Panel

References:

  1. S. Food and Drug Administration. (2018, March 6). Preventable adverse drug reactions: A focus on drug interactions. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions
  2. Montastruc, J.-L., Lafaurie, M., de Canecause, C., et al. (2021). Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology, 87(11), 4334–4340. https://doi.org/10.1111/bcp.14855
  3. Brown MT, Bussell JK. Medication adherence: WHO cares?. Mayo Clinic Proceedings. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575.
  4. Hakkarainen KM, Hedna K, Petzold M, Hägg S. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions – a meta-analysis. PLoS ONE. 2012;7(3):e33236. doi:10.1371/journal.pone.0033236.
  5. Cacabelos, R., Cacabelos, N., & Carril, J. C. (2019). The role of pharmacogenomics in adverse drug reactions. Expert Review of Clinical Pharmacology, 12(5), 407–442. https://doi.org/10.1080/17512433.2019.1601875
  6. Swen, J. J., van der Wouden, C. H., Manson, L. E., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347–356. https://doi.org/10.1016/S0140-6736(23)00102-0
  7. Ji, Y., Skierka, J. M., Blommel, J. H., et al. (2016). Preemptive pharmacogenomic testing for precision medicine: A comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. Journal of Molecular Diagnostics, 18(3), 438–445. https://doi.org/10.1016/j.jmoldx.2016.01.003